Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Top Cited Papers
- 1 September 2018
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 8 (9), 1069-1086
- https://doi.org/10.1158/2159-8290.cd-18-0367
Abstract
Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community to begin to envision potentially curative therapeutic approaches. However, the remarkable responses to immunotherapies are currently limited to a minority of patients and indications, highlighting the need for more effective and novel approaches. Indeed, an extraordinary amount of preclinical and clinical investigation is exploring the therapeutic potential of negative and positive costimulatory molecules. Insights into the underlying biological mechanisms and functions of these molecules have, however, lagged significantly behind. Such understanding will be essential for the rational design of next-generation immunotherapies. Here, we review the current state of our understanding of T-cell costimulatory mechanisms and checkpoint blockade, primarily of CTLA4 and PD-1, and highlight conceptual gaps in knowledge. Significance: This review provides an overview of immune checkpoint blockade therapy from a basic biology and immunologic perspective for the cancer research community. Cancer Discov; 8(9); 1–18. ©2018 AACR.Keywords
This publication has 171 references indexed in Scilit:
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- ICOS Receptor Instructs T Follicular Helper Cell versus Effector Cell Differentiation via Induction of the Transcriptional Repressor Bcl6Immunity, 2011
- Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunityProceedings of the National Academy of Sciences of the United States of America, 2010
- CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell helpNature, 2009
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DCEuropean Journal of Immunology, 2009
- Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissuesProceedings of the National Academy of Sciences of the United States of America, 2009
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2008
- Generation of T Follicular Helper Cells Is Mediated by Interleukin-21 but Independent of T Helper 1, 2, or 17 Cell LineagesImmunity, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007